Liquidia Corp- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Liquidia Corp 公司

Liquidia Corporation 是一家生物製藥公司。該公司專注於開發、製造和商業化滿足未滿足患者需求的產品，重點是罕見的心肺疾病，例如肺動脈高壓 (PAH) 和與間質性肺病相關的肺動脈高壓 (PH-ILD)。該公司通過其全資運營子公司 Liquidia Technologies, Inc. 和 Liquidia PAH, LLC 開展業務。其專有的 PRINT 技術是一種粒子工程平臺，可精確生產均勻的藥物顆粒。其主要候選產品是用於治療 PAH 和 PH-ILD 的 YUTREPIA。YUTREPIA 是一種吸入式曲前列尼爾乾粉製劑，採用 PRINT 設計，通過增強深肺輸送，同時使用方便的乾粉吸入器 (DPI) 並實現比當前吸入療法標示劑量更高的劑量水平，從而改善曲前列尼爾的治療特性。

公司簡介

公司代碼LQDA

公司名稱Liquidia Corp

上市日期Jul 26, 2018

成立日期2020

CEODr. Roger A. Jeffs, Ph.D.

員工數量157

證券類型Ordinary Share

年結日Jul 26

公司地址419 Davis Drive

城市MORRISVILLE

上市交易所NASDAQ Capital Market Consolidated

國家United States of America

郵編27560

電話19193284400

網址https://www.liquidia.com/

公司代碼LQDA

上市日期Jul 26, 2018

成立日期2020

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Dr. Roger A. Jeffs, Ph.D.

Chief Executive Officer, Director

2.13M

+1.85%

Mr. Russell Schundler, J.D.

General Counsel, Secretary

372.72K

+2.59%

Mr. Rajeev Saggar, M.D.

Chief Medical Officer

266.92K

+3.92%

Mr. Scott Moomaw

Chief Commercial Officer

216.08K

+4.00%

Mr. Jason Adair

Chief Business Officer

161.93K

+5.42%

Mr. Michael Kaseta

Chief Financial Officer, Chief Operating Officer

146.34K

+10.17%

Mr. Damian Degoa

Independent Director

66.11K

+38.55%

Mr. Arthur S. Kirsch

Independent Director

50.40K

+57.49%

Dr. Joanna C. Horobin

Independent Director

18.40K

--

Ms. Katherine (Katie) Rielly-Gauvin

Independent Director

18.40K

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Roger A. Jeffs, Ph.D.

Chief Executive Officer, Director

2.13M

+1.85%

Mr. Russell Schundler, J.D.

General Counsel, Secretary

372.72K

+2.59%

Mr. Rajeev Saggar, M.D.

Chief Medical Officer

266.92K

+3.92%

Mr. Scott Moomaw

Chief Commercial Officer

216.08K

+4.00%

Mr. Jason Adair

Chief Business Officer

161.93K

+5.42%

Mr. Michael Kaseta

Chief Financial Officer, Chief Operating Officer

146.34K

+10.17%

收入明細

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

暫無數據

地區USD

名稱

營收

佔比

United States

14.00M

0.00%

業務

地區

暫無數據

股東統計

更新時間: 5月16日週五

持股股東

股東類型

持股股東

佔比

Caligan Partners, LP

9.50%

Manning (Paul B.)

7.21%

BlackRock Institutional Trust Company, N.A.

4.91%

Farallon Capital Management, L.L.C.

4.67%

The Vanguard Group, Inc.

4.04%

Other

69.67%

持股股東

佔比

Caligan Partners, LP

9.50%

Manning (Paul B.)

7.21%

BlackRock Institutional Trust Company, N.A.

4.91%

Farallon Capital Management, L.L.C.

4.67%

The Vanguard Group, Inc.

4.04%

Other

69.67%

股東類型

持股股東

佔比

Hedge Fund

30.69%

Investment Advisor/Hedge Fund

15.97%

Investment Advisor

12.67%

Individual Investor

11.55%

Research Firm

3.48%

Corporation

2.69%

Private Equity

1.78%

Bank and Trust

0.26%

Pension Fund

0.21%

Other

20.70%

機構持股

更新時間: 3月4日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q1

344

64.23M

75.45%

-9.89M

2024Q4

344

63.62M

75.17%

-10.09M

2024Q3

335

73.31M

89.39%

+16.42M

2024Q2

318

66.67M

87.88%

+4.98M

2024Q1

302

59.34M

79.61%

+7.64M

2023Q4

256

48.15M

70.41%

+4.56M

2023Q3

236

40.52M

62.49%

-5.87M

2023Q2

223

41.12M

63.56%

-6.16M

2023Q1

214

42.01M

65.00%

-5.41M

2022Q4

210

41.20M

63.89%

-7.92M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

Caligan Partners, LP

8.12M

9.52%

--

Dec 31, 2024

Manning (Paul B.)

6.15M

7.21%

+316.72K

+5.43%

Sep 30, 2024

BlackRock Institutional Trust Company, N.A.

4.18M

4.9%

+416.76K

+11.07%

Dec 31, 2024

Farallon Capital Management, L.L.C.

3.29M

3.86%

--

Dec 31, 2024

The Vanguard Group, Inc.

3.55M

4.16%

+115.37K

+3.36%

Dec 31, 2024

Findell Capital Management LLC

3.08M

3.61%

-113.54K

-3.56%

Dec 31, 2024

Opaleye Management Inc.

1.70M

1.99%

--

Dec 31, 2024

Jeffs (Roger A)

2.19M

2.56%

+206.98K

+10.46%

Jan 14, 2025

Legend Aggregator LP

1.86M

2.18%

-5.32M

-74.10%

Dec 31, 2024

State Street Global Advisors (US)

1.81M

2.12%

-363.63K

-16.72%

Dec 31, 2024

持股ETF

更新時間: 6月6日週五

機構名稱

佔比

Invesco Pharmaceuticals ETF

2.76%

Invesco Dorsey Wright Healthcare Momentum ETF

1.97%

SPDR S&P Pharmaceuticals ETF

1.71%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.11%

ALPS Medical Breakthroughs ETF

1.08%

Virtus LifeSci Biotech Clinical Trials ETF

1.01%

iShares U.S. Pharmaceuticals ETF

0.3%

First Trust Small Cap Growth AlphaDEX Fund

0.27%

SPDR S&P Kensho New Economies Composite ETF

0.22%

iShares Micro-Cap ETF

0.21%

Invesco Pharmaceuticals ETF

佔比2.76%

Invesco Dorsey Wright Healthcare Momentum ETF

佔比1.97%

SPDR S&P Pharmaceuticals ETF

佔比1.71%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比1.11%

ALPS Medical Breakthroughs ETF

佔比1.08%

Virtus LifeSci Biotech Clinical Trials ETF

佔比1.01%

iShares U.S. Pharmaceuticals ETF

佔比0.3%

First Trust Small Cap Growth AlphaDEX Fund

佔比0.27%

SPDR S&P Kensho New Economies Composite ETF

佔比0.22%

iShares Micro-Cap ETF

佔比0.21%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Liquidia Corp

13.100USD

Liquidia Corp

13.100

概覽

公司